Arana files IND

By Dylan Bushell-Embling
Tuesday, 30 September, 2008

Arana Therapeutics [ASX: AAH] has submitted an IND to the FDA for its candidate ART621 for rheumatoid arthritis.

As part of the IND application, a Phase II dose trial of the anti-TNF drug will be conducted in a multi-centre trial in 200 patients.

Arana expects to begin recruitment for the study later this year, pending approval from the FDA. Quintiles has been named as the contract research manager.

Organoid platform enables closer study of bat-borne viruses

Reconstructing bat organ physiology in the lab lets scientists explore how zoonotic viruses work...

Global study finds 250 genes linked to OCD

Researchers say they have found the genes linked to obsessive compulsive disorder (OCD), after...

TGA approves therapy for paediatric growth hormone deficiency

The TGA has approved SKYTROFA as a treatment for growth failure in children and adolescents aged...

Content from other channels on our network

Increasing sensor life in harsh conditions

Enabling OT continuous monitoring

Central Coast Council completes first remote sewer inspection

Ghost Bat a major milestone for local defence manufacturing

From smart to vulnerable: The hidden costs of the digitalisation of utilities

Victorian home demonstrates grid resilience solution

Recycled water to keep Victorian sporting grounds green

Productivity Summit announcement welcomed

ABB receives EPD status for gearless mill drive ring motor

From Crisis to Control: AI Offers New Hope for Water Management

GNT shows how plant-based colours can liven up snacks

Getting a handle on a shrink bag for turkey

Six on the shelf: from frozen snacks to GF treats

Visibly conveying freshly roasted coffee direct to the consumer

Sobering up with the latest wine trends